Abstract
Dysregulated host responses to infection can lead to organ dysfunction and sepsis, causing millions of deaths globally each year. To alleviate this burden, improved prognostication and biomarkers of response are urgently needed. We investigated the use of whole blood transcriptomics for stratification of patients with severe infection by integrating data from 3,149 samples of sepsis patients and healthy individuals into a gene expression reference map. We used this map to derive a quantitative sepsis response signature (SRSq) score reflective of immune dysfunction and predictive of clinical outcomes, which can be estimated using a 19-gene signature. Finally, we built a machine learning framework, SepstratifieR, to deploy SRSq in sepsis, H1N1 influenza, and COVID-19, demonstrating clinically relevant stratification across diseases and revealing the physiological alterations linking immune dysregulation to mortality. Our method enables early identification of individuals with dysfunctional immune profiles, thus bringing us closer to precision medicine in infection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded in whole, or in part, by the Medical Research Council (MR/V002503/1), Wellcome Trust Investigator Award (204969/Z/16/Z), Wellcome Trust core funding to the Wellcome Sanger Institute (Grant number WT206194), Wellcome Trust Grants (090532/Z/09/Z and 203141/Z/16/Z) to core facilities of the Wellcome Centre for Human Genetics, and NIHR Oxford Biomedical Research Centre.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this work was given by the following UK Research Ethics Committees: Scotland A Research Ethics Committee (05/MRE00/38), Berkshire Research Ethics Committee (08/H0505/78), and Oxfordshire Research Ethics Committee (06/Q1605/55).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵Δ A full lists of participants and affiliations appears at the end of the paper
Data Availability
All datasets used in this study are publicly available, with accession numbers listed in the manuscript. All data produced in the present study are available upon request and will be made publicly available upon publication.